VIValeria Iannone

Valeria Iannone

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Valeria Iannone has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The effect of aldafermin expressing-Escherichia coli Nissle 1917 along with dietary change on visceral adipose tissue in MASLD mouse model

    by Valeria Iannone, Maija Vaittinen, Carlos Gómez-Gallego, Santtu Mikkonen, Johnson Lok, Giuseppe D’aUria, Ruben Vazquez-Uribe, Ida Tikkanen, Morten Otto Alexander Sommer, Hani El-Nezami, et al.

    Background: Visceral adipose tissue (VAT) accumulation in obesity has been implicated as a key factor in the development of metabolic dysfunction-associated steatotic liver disease (MASLD). Apart from lifestyle change interventions, there is no effective therapy against MASLD. In this study, the effect of a novel microbial therapy along with dietary change on VAT and VAT-liver crosstalk was evaluated in a MASLD mouse model. Methods: MASLD was induced by feeding eighteen C57BL/6J male mice with the American Lifestyle-Induced Obesity diet for fourteen weeks. Subsequently, during the following seven weeks, all mice were switched to standard diet and the intervention group received single gelatine cubes containing 109 CFU each of aldafermin-expressing Escherichia coli Nissle (EcNA, n = 6); while the control groups received either 109 CFU/gelatine cube of non-modified Escherichia coli Nissle (EcN, n = 6) or gelatin cube with no treatment (CTRL, n = 6). The effect of EcNA on epididymal visceral adipose tissue (eVAT) morphology was evaluated by histology and the gene expression profile in eVAT and liver by RNA-sequencing analysis. Results: After seven weeks of intervention, EcNA, when compared to CTRL group, induced smaller adipocytes (p-value = 0.0217 for diameter, p-value = 0.0386 for area). Gene Set Enrichment Analysis in eVAT showed significant upregulation of fatty acid metabolism (FDR-adjusted p-value = 0.001), oxidative phosphorylation (FDR-adjusted p-value < 2.2e-16), peroxisome (FDR-adjusted p-value = 0.0185), and thermogenesis (FDR-adjusted p-value = 0.0199) pathways when EcNA was compared to EcN group. In addition, the impact of EcNA in eVAT-liver gene expression crosstalk was underlined by the upregulation of Bcl6 and Cnst expression in both tissues when EcNA was compared to CTRL and EcN groups. Conclusions: These results support the beneficial effects of EcNA, along with dietary change intervention, in obesity-associated MASLD. This microbial therapy could potentially boost the improvements induced by dietary change in eVAT metabolism and its crosstalk with the liver.


  • Open Access

    Engineered Escherichia coli Nissle 1917 Expressing IGF1 and FGF19 Reduce Liver Fat Accumulation and Restore Microbial Equilibrium in a Metabolic Dysfunction-Associated Steatotic Liver Disease Mice Model

    by Johnson Lok, Valeria Iannone, Carlos Gómez-Gallego, Ruben Vazquez-Uribe, Morten Otto Alexander Sommer, Marjukka Kolehmainen, Hani El-Nezami

    Background and objectives: Endocrine dysregulation and intestinal microbiota unbalance are commonly associated with metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to investigate the effectiveness of engineered probiotic Escherichia coli Nissle (EcN) 1917 expressing various hormones (IGF1, GLP-1, FGF19, Adiponectin) downregulated in MASLD as a potential therapeutic. Methods: 41 C57BL/6J mice underwent 14 weeks of a high-fat diet intervention for MASLD development. The mice were then separated into seven groups and underwent 7 weeks of probiotic intervention while under the control diet. The mice were grouped as follows: (1) without probiotic; (2) EcN without hormone expression; (3–6) EcN expressing IGF1, GLP-1, FGF19, and Adiponectin, respectively; and (7) liraglutide treatment. Liver fat was measured using MRI and the Oil-Red-O staining of liver histological samples. 16s rRNA sequencing was used to investigate the bacterial composition in mice cecum. Results: Mice receiving EcN expressing IGF1, GLP-1, and FGF19 were effective at reducing liver fat accumulation. Microbiota compositions were different between groups, and the microbial communities of mice receiving EcN expressing IGF1 and FGF19 had higher observed richness. Mice receiving EcN-IGF1 had lower abundance of sulfate-reducing bacteria (Desulfobacterota) associated with gut inflammation and higher abundance of butyrate-producing bacteria (Roseburia sp.) and Lactobacillus reuteri. Mice receiving EcN-FGF19 had lower abundance of bacteria associated with intestinal inflammation (Coriobacteriia) and higher abundance of SCFA-producing bacteria (Roseburia sp. and Blautia sp.) and plasma propionate levels. Discussion: EcN expressing IGF1 and FGF19 have the potential to reduce liver fat accumulation and restore microbial equilibrium. This may be a combined effect of hormones and EcN, as a probiotic, thereby improving gut endocrine and immune functions.


  • Open Access

    Role of microbiota and related metabolites in gastrointestinal tract barrier function in NAFLD

    by Maria Victoria Fernandez-Cantos, Diego Garcia-Morena, Valeria Iannone, Hani El-Nezami, Marjukka Kolehmainen, Oscar P. Kuipers

    The Gastrointestinal (GI) tract is composed of four main barriers: microbiological, chemical, physical and immunological. These barriers play important roles in maintaining GI tract homeostasis. In the crosstalk between these barriers, microbiota and related metabolites have been shown to influence GI tract barrier integrity, and alterations of the gut microbiome might lead to an increase in intestinal permeability. As a consequence, translocation of bacteria and their products into the circulatory system increases, reaching proximal and distal tissues, such as the liver. One of the most prevalent chronic liver diseases, Nonalcoholic Fatty Liver Disease (NAFLD), has been associated with an altered gut microbiota and barrier integrity. However, the causal link between them has not been fully elucidated yet. In this review, we aim to highlight relevant bacterial taxa and their related metabolites affecting the GI tract barriers in the context of NAFLD, discussing their implications in gut homeostasis and in disease.